{"entity":{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","aka":[],"tldr":"A phase 1/2 trial of Fludarabine and Cyclophosphamide in neuroblastoma, run by Beijing Biotech, now recruiting.","summary":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma is a phase 1/2 interventional study registered as NCT07502287 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DTNB-NK, Fludarabine and Cyclophosphamide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07502287","url":"https://clinicaltrials.gov/study/NCT07502287"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07502287","phase":"1/2","setting":"A Phase 1/Phase 2, Open-Label Study of BiomarkerInformed, Allogeneic Dual-Target GD2/B7-H3 (CD276) CAR-NK Cells in Children and Young Adults With Relapsed or Refractory Neuroblastoma","sponsor":"Beijing Biotech","enrolled":36,"outcomes":[]},"route":"/trials/nct07502287/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}